This is one of our mid term winner as our return is more than 260% with dividend yielded across 4 to 5 years. Their business model remained a growth stock and recent Europe approved its products will stir growth. Current PE of 17 times remained manageable. We will continue to hold on for this stock.
We have a hold call on Apex Healthcare
This site uses Akismet to reduce spam. Learn how your comment data is processed.
J&J Investment Co. 
Leave a Reply